Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021

Veronique Yvette Miendje Deyi; Ruffin Ntounda; Hubert Louis; Nsimire L Kahegeshe; Marcel Nkuize; Alain Burette; Kalliroy Kotilea; Marc Van Gossum; Myriam Delhaye; Patrick Bontems

doi:10.1016/j.diagmicrobio.2022.115855

Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021

Diagn Microbiol Infect Dis. 2023 Feb;105(2):115855. doi: 10.1016/j.diagmicrobio.2022.115855. Epub 2022 Nov 8.

Authors

Affiliations

¹ Laboratoire Hospitalier Universitaire de Bruxelles, (LHUB-ULB) Department of Microbiology, Université Libre de Bruxelles, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium. Electronic address: veronique.miendjedeyi@lhub-ulb.be.
² Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium.
³ Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium.
⁴ Gastroenterology Unit, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
⁵ Gastroenterology Department, Centre Hospitalier Inter régional Edith Cavell, sites de la Basilique et E. Cavell, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium.
⁶ Gastroenterology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium.
⁷ Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
⁸ Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Gastroenterology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Belgian Helicobacter and Microbiota Study Group (BHMSG), Brussels, Belgium.

PMID: 36462449
DOI: 10.1016/j.diagmicrobio.2022.115855

Abstract

This manuscript summarizes current primary resistance of Helicobacter pylori to antibiotics in Brussels in 2021. Resistance rates were estimated at 18% for clarithromycin, 24% for levofloxacin, 52% for metronidazole, and 0% for amoxicillin and tetracycline. When compared to 2016, resistance rates remain stable, except an increase of 30% for metronidazole.

Keywords: Helicobacter pylori, Antimicrobial resistance, Clarithromycin; metronidazole.

MeSH terms

Amoxicillin / pharmacology
Anti-Bacterial Agents / pharmacology
Clarithromycin / pharmacology
Drug Resistance, Bacterial
Drug Resistance, Multiple, Bacterial
Helicobacter Infections* / drug therapy
Helicobacter pylori*
Humans
Levofloxacin
Metronidazole / pharmacology
Microbial Sensitivity Tests

Substances

Metronidazole
Anti-Bacterial Agents
Amoxicillin
Clarithromycin
Levofloxacin